Abstract
Iruplinalkib (Trade name: 启欣可®; Code name: WX-0593), a highly selective oral anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI), is being developed by Qilu Pharmaceutical Co., Ltd. for the treatment of ALK-positive (ALK+) or ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). In June 2023, iruplinalkib was approved in China for the treatment of patients with locally advanced or metastatic ALK+ NSCLC who have progressed after prior crizotinib therapy or are intolerant to crizotinib. This article summarizes the milestones in the development of iruplinalkib leading to this first approval for the treatment of patients with locally advanced or metastatic ALK+ NSCLC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yang Y, Zheng Q, Wang X, et al. Iruplinalkib (WX-0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer. Invest New Drugs. 2023;41(2):254–66.
Shi Y, Fang J, Hao X, et al. Safety and activity of WX-0593 (iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022. https://doi.org/10.1038/s41392-021-00841-8.
Liu X, Zhang L, Wan H, et al. Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations. Bioorg Med Chem Lett. 2022;66: 128730.
Li W, Zhang J, Wang Z, et al. Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. J Natl Cancer Cent. 2021;1(4):123–31.
Qilu Pharmaceutical Co Ltd. Iruplinalkib: Chinese prescribing information 2023. https://www.hnysfww.com/mobile/prod.php?code=T040094. Accessed 28 Sep 2023.
National Medical Products Administration. The State Food and Drug Administration approved the marketing of iruplinalkib tablets 2023. https://www.nmpa.gov.cn/yaowen/ypjgyw/20230628200648143.html. Accessed 28 Sep 2023.
National Medical Products Administration. Iruplinalkib tablets (30mg & 60mg): NMPA approval notices. 2023. https://www.nmpa.gov.cn/. Accessed 28 Sep 2023.
World Health Organization. Pre-stems: suffixes used in the selection of INN - March 2020. 2020. https://www.who.int/. Accessed 30 Oct 2023.
Zheng SS, Zheng QM, Dong X, et al. Pharmacodynamics of WX-0593 combined with bevacizumab biosimilar on human lung cancer xenograft mouse models [abstract no. 5458]. Cancer Res. 2022;82(12 Suppl).
Zheng Q, Chen D, Wang X, et al. WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations. Ann Transl Med. 2022;10(12):696.
Shi Y, Chen J, Yang R, et al. A randomized, phase 3 study of iruplinalkib (WX-0593) vs crizotinib in locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC) [abstract no. OA03.05 plus presentation]. In: World Conference on Lung Cancer. 2023.
Shi Y, Chen J, Zhang H, et al. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). BMC Med. 2023. https://doi.org/10.1186/s12916-023-02738-5.
Shi Y, Cheng Y, Chen J, et al. A phase II clinical study on the efficacy and safety of iruplinalkib (WX-0593) in the treatment of crizotinib-resistant/crizotinib-naïve patients with ROS1-positive non-small cell lung cancer [abstract no. 13878]. In: 25th National Clinical Oncology Congress and 2022 CSCO Academic Annual Meeting. 2022.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability
Not applicable.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Keam, S.J. Iruplinalkib: First Approval. Drugs 83, 1717–1721 (2023). https://doi.org/10.1007/s40265-023-01970-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-023-01970-w